We retrospectively evaluated the association between the clinical efficacy of ALK-TKIs and FGFR1 or FGF2 expression levels using data from the J-ALEX phase III study of patients with ALK + NSCLC treated with alectinib or crizotinib17. The gene discussed is ALK; the disease is non-small cell lung carcinoma.